arrow
A

Andreas Hahn

university medicine rostock
H指数:27
被引数:3,407

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland—part I—systematic literature review and existing evidence

德国、奥地利和瑞士关于Onasemnogene Abeparvovec治疗脊髓性肌萎缩基因疗法的德尔菲共识——第一部分——系统文献综述与现有证据

2025-11-240
OA
Evaluation of Each Three Entamoeba histolytica- and Strongyloides stercoralis-Specific Real-Time PCR Assays Applying Test Comparisons Without Reference Standards

对每种分别针对溶组织内阿米巴(Entamoeba histolytica)和犬钩虫(Strongyloides stercoralis)的实时PCR检测方法的评估,应用了无参考标准的测试比较。

2025-08-240
PRE
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
2024-12-010
PRE
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)
2024-11-011
OAAI
A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidosis (PRONTO): Evaluation of different assessments
2024-02-010
PRE
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry

较高剂量的alglucosidase alfa与婴儿型庞贝病 (IOPD) 的总生存率改善相关: 来自庞贝注册中心的数据

2023-12-065
OAAI
Screening for Resistant Bacteria, Antimicrobial Resistance Genes, Sexually Transmitted Infections and Schistosoma spp. in Tissue Samples from Predominantly Vaginally Delivered Placentae in Ivory Coast and Ghana
2023-07-301
OAAI
Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany

新生儿筛查SMA-从试点项目到德国的全国筛查

2022-11-2819
OAAI